Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of HCV genotypes in Poland - the EpiTer study.
Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K. Flisiak R, et al. Among authors: olszok i. Clin Exp Hepatol. 2016 Dec;2(4):144-148. doi: 10.5114/ceh.2016.63871. Epub 2016 Nov 28. Clin Exp Hepatol. 2016. PMID: 28856279 Free PMC article.
Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study.
Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K. Flisiak R, et al. Among authors: olszok i. Clin Exp Hepatol. 2016 Dec;2(4):138-143. doi: 10.5114/ceh.2016.63870. Epub 2016 Nov 28. Clin Exp Hepatol. 2016. PMID: 28856278 Free PMC article.
Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
Flisiak R, Łucejko M, Mazur W, Janczewska E, Berak H, Tomasiewicz K, Mozer-Lisewska I, Kozielewicz D, Gietka A, Sikorska K, Wawrzynowicz-Syczewska M, Nowak K, Zarębska-Michaluk D, Musialik J, Simon K, Garlicki A, Pleśniak R, Baka-Ćwierz B, Olszok I, Augustyniak K, Stolarz W, Białkowska J, Badurek A, Piekarska A. Flisiak R, et al. Among authors: olszok i. Adv Med Sci. 2017 Sep;62(2):387-392. doi: 10.1016/j.advms.2017.04.004. Epub 2017 May 26. Adv Med Sci. 2017. PMID: 28554119
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.
Janczewska E, Flisiak R, Zarebska-Michaluk D, Kozielewicz D, Berak H, Dobracka B, Librant-Suska M, Lojewski W, Jurczyk K, Musialik J, Postawa-Klosińska B, Wroblewski J, Augustyniak K, Dudziak M, Olszok I, Ruszala A, Pisula A, Lapinski T, Kryczka W, Horban A, Dobracki W. Janczewska E, et al. Among authors: olszok i. Medicine (Baltimore). 2015 Sep;94(38):e1411. doi: 10.1097/MD.0000000000001411. Medicine (Baltimore). 2015. PMID: 26402801 Free PMC article.
[Polish multicenter study on safety and efficacy of adefovir dipivoxil in the treatment of lamivudine resistant chronic hepatitis B in adults (HEP 2008)].
Krygier R, Flisiak R, Bacia V, Baka-Cwierz B, Bluszcz-Roznowska A, Boroń-Kaczmarska A, Brzostek T, Deroń Z, Durlik M, Janczewska-Kazek E, Kalinowska A, Mach T, Olszok I, Pisula A, Wawrzynowicz-Syczewska M, Juszczyk J. Krygier R, et al. Among authors: olszok i. Przegl Epidemiol. 2011;65(4):615-20. Przegl Epidemiol. 2011. PMID: 22390049 Clinical Trial. Polish.
[Ehrlichiosis].
Bluszcz-Roznowska A, Olszok I, Kucharz EJ. Bluszcz-Roznowska A, et al. Among authors: olszok i. Przegl Lek. 2005;62(12):1529-31. Przegl Lek. 2005. PMID: 16786789 Review. Polish.
[Tularemia].
Olszok I, Bluszcz-Roznowska A, Kucharz EJ. Olszok I, et al. Pol Arch Med Wewn. 2005 Feb;113(2):185-90. Pol Arch Med Wewn. 2005. PMID: 16209241 Review. Polish. No abstract available.
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study. Ferenci P, et al. N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4. N Engl J Med. 2014. PMID: 24795200 Free article. Clinical Trial.
[Giardiasis].
Olszok I, Kucharz EJ. Olszok I, et al. Przegl Lek. 1996;53(7):579-81. Przegl Lek. 1996. PMID: 8975296 Review. Polish.
11 results